Therapeutic immunization with an inactivated HIV-1 immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects

被引：16

作者：

Fernandez-Cruz, E

Moreno, S

Navarro, J

Clotet, B

Bouza, E

Carbone, J

Peña, JM

Molina, JP

Podzamczer, D

Rubio, R

Ocaña, I

Pulido, F

Viciana, P

Maradona, JA

Blazquez, R

Barros, C

Quereda, C

Rodriguez-Sainz, C

Gil, J

Abad, ML

Díaz, L

Cantó, C

Muñoz, MA

Ferrer, E

Jou, A

Sirera, G

Díaz, M

Lopez, F

Gatell, JM

Gonzalez-Lahoz, J

机构：

[1] Univ Madrid, Hosp Gen Gregorio Maranon, Div Immunol, Madrid 28007, Spain

[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain

[3] Hosp Badalona Germans Trias & Pujol, Badalona, Spain

[4] Hosp La Paz, Madrid, Spain

[5] Hosp 12 Octubre, E-28041 Madrid, Spain

[6] Hosp Gen Valle Hebron, Barcelona, Spain

[7] Hosp Virgen Rocio, Seville, Spain

[8] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain

[9] Hosp Morales Meseguer, Murcia, Spain

[10] Nufarm 21, Madrid, Spain

[11] Hosp Clin Barcelona, Barcelona, Spain

[12] Inst Salud Carlos III, Madrid, Spain

来源：

VACCINE | 2004年 / 22卷 / 23-24期

关键词：

HIV-1; immunogen; viral load; therapeutic vaccination;

D O I：

10.1016/j.vaccine.2004.03.040

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To determine whether the addition of an inactivated-gp120-depleted HIV-1 Immunogen to antiretrovirals (ARTs) conferred a beneficial effect on delaying time to virologic failure relative to that obtained by ARTs alone, a phase II clinical trial was performed in 243 asymptomatic, ART naive, HIV-1 seropositive adults. The Cox model showed that HIV-1 Immunogen treatment was associated with a 34% decrease in the risk of virologic failure (P = 0.056). When the analysis incorporated baseline HIV-RNA stratification the risk of virologic failure in the HIV-1 Immunogen Arm was significantly reduced a 37% compared to the IFA placebo Arm (P = 0.034). The data suggest that therapeutic immunization plus ARTs could influence virologic control. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：2966 / 2973

页数：8

共 30 条

[1]

BLOWER SM, 2003, AIDSSCIENCE, V3

[2] HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant [J].

Choi, DJ ;

Dube, S ;

Spicer, TP ;

Slade, HB ;

Jensen, FC ;

Poiesz, BJ .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (04) :357-361

[3] IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].

CONDRA, JH ;

SCHLEIF, WA ;

BLAHY, OM ;

GABRYELSKI, LJ ;

GRAHAM, DJ ;

QUINTERO, JC ;

RHODES, A ;

ROBBINS, HL ;

ROTH, E ;

SHIVAPRAKASH, M ;

TITUS, D ;

YANG, T ;

TEPPLER, H ;

SQUIRES, KE ;

DEUTSCH, PJ ;

EMINI, EA .

NATURE, 1995, 374 (6522) :569-571

[4] Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial [J].

Davey, RT ;

Murphy, RL ;

Graziano, FM ;

Boswell, SL ;

Pavia, AT ;

Cancio, M ;

Nadler, JP ;

Chaitt, DG ;

Dewar, RL ;

Sahner, DK ;

Duliege, AM ;

Capra, WB ;

Leong, WP ;

Giedlin, MA ;

Lane, HC ;

Kahn, JO .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (02) :183-189

[5] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].

Finzi, D ;

Blankson, J ;

Siliciano, JD ;

Margolick, JB ;

Chadwick, K ;

Pierson, T ;

Smith, K ;

Lisziewicz, J ;

Lori, F ;

Flexner, C ;

Quinn, TC ;

Chaisson, RE ;

Rosenberg, E ;

Walker, B ;

Gange, S ;

Gallant, J ;

Siliciano, RF .

NATURE MEDICINE, 1999, 5 (05) :512-517

[6] What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: Issues involving surrogate end points in phase 3 trials [J].

Gilbert, PB ;

DeGruttola, VG ;

Hudgens, MG ;

Self, SG ;

Hammer, SM ;

Corey, L .

JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (02) :179-193

[7] Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts -: A randomized controlled trial [J].

Kahn, JO ;

Cherng, DW ;

Mayer, K ;

Murray, H ;

Lagakos, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (17) :2193-2202

[8] EFFECT OF GAMMA-IRRADIATION ON THE HUMAN IMMUNODEFICIENCY VIRUS AND HUMAN COAGULATION PROTEINS [J].

KITCHEN, AD ;

MANN, GF ;

HARRISON, JF ;

ZUCKERMAN, AJ .

VOX SANGUINIS, 1989, 56 (04) :223-229

[9] Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection [J].

Lange, CG ;

Lederman, MM ;

Medvik, K ;

Asaad, R ;

Wild, M ;

Kalayjian, R ;

Valdez, H .

AIDS, 2003, 17 (14) :2015-2023

[10] Safety and immunogenicity of REMUNE™ in HIV-infected Thai subjects [J].

Limsuwan, A ;

Churdboonchart, V ;

Moss, RB ;

Sirawaraporn, W ;

Sutthent, R ;

Smutharaks, B ;

Glidden, D ;

Trauger, R ;

Theofan, G ;

Carlo, D .

VACCINE, 1998, 16 (2-3) :142-149

← 1 2 3 →